|
Human breast cancer cells treated left to right with dasatinib. The same samples are dyed to highlight different proteins. Photo courtesy of Dr. Corey. |
Researchers at Northwestern University are pioneering ways to shoot out the tires from breast cancer’s getaway car in a high-speed chase of drug assassins and carcinogenic criminals.
|
Dr. Seth Corey, M.D. |
That’s because breast cancer itself doesn’t kill until it metastasizes, or travels, to other sensitive organs, invades and then grows. But a new clue to stopping this destructive spree surprisingly came from children.
Dr. Seth Corey is a pediatric oncologist at Children’s Memorial Hospital and professor of cellular and molecular biology at Northwestern University’s Feinberg School of Medicine. He and his researchers saw similarities between the travels of breast cancer and another notorious roamer – leukemia. They found that dasatinib, a drug already used to eliminate leukemia in the bone marrow, may also prevent mobility in breast cancer, keeping it from jumping the mammary ship to invade vital organs and kill.
But even though dasatinib is FDA-approved for the treatment of leukemia, the likelihood of your doctor prescribing it for breast cancer just yet is slim. The Northwestern research team hopes to take advantage of dasatinib’s clinical breast cancer trials to determine what responds best. By mapping the biological signatures of varying cancer types this way, fingerprints of these malignant flight-risks to assist in diagnosis and further targeted treatment may not be far off.